Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
October 9, 2019Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
September 24, 2019Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma
August 22, 2019Targovax ASA: Second quarter and first half 2019 results
August 12, 2019Targovax ASA: Announcement of second quarter and first half results 2019